IS5946A - Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform - Google Patents

Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform

Info

Publication number
IS5946A
IS5946A IS5946A IS5946A IS5946A IS 5946 A IS5946 A IS 5946A IS 5946 A IS5946 A IS 5946A IS 5946 A IS5946 A IS 5946A IS 5946 A IS5946 A IS 5946A
Authority
IS
Iceland
Prior art keywords
amorphous
transformed
semi
particles
crystalline form
Prior art date
Application number
IS5946A
Other languages
English (en)
Inventor
Bisrat Mikael
Moshashee Saeed
Nyqvist Håkan
Demirbüker Mustafa
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS5946A publication Critical patent/IS5946A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Recrystallisation Techniques (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS5946A 1998-11-23 2001-05-18 Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform IS5946A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
PCT/SE1999/002154 WO2000030614A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Publications (1)

Publication Number Publication Date
IS5946A true IS5946A (is) 2001-05-18

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5946A IS5946A (is) 1998-11-23 2001-05-18 Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform

Country Status (27)

Country Link
US (1) US6475524B1 (is)
EP (1) EP1133285B1 (is)
JP (1) JP4447169B2 (is)
KR (1) KR100697780B1 (is)
CN (1) CN1198592C (is)
AT (1) ATE318583T1 (is)
AU (1) AU767313B2 (is)
BR (1) BR9915592A (is)
CA (1) CA2349633C (is)
CY (1) CY1105609T1 (is)
CZ (1) CZ20011778A3 (is)
DE (1) DE69930158T2 (is)
DK (1) DK1133285T3 (is)
EE (1) EE200100275A (is)
ES (1) ES2258865T3 (is)
HU (1) HUP0104182A2 (is)
IL (2) IL143040A0 (is)
IS (1) IS5946A (is)
NO (1) NO20012514L (is)
NZ (1) NZ511494A (is)
PL (1) PL348523A1 (is)
PT (1) PT1133285E (is)
SE (1) SE9804000D0 (is)
SK (1) SK7032001A3 (is)
TR (1) TR200101424T2 (is)
WO (1) WO2000030614A1 (is)
ZA (1) ZA200103946B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
WO2002051381A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Substance poreuse et son procede de fabrication
WO2003004142A1 (en) * 2001-07-02 2003-01-16 Micro & Nano Materials Sagl Process for the production of micro and/or nano particles
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN1913882A (zh) * 2004-02-06 2007-02-14 Meda制药有限及两合公司 用抗胆碱能药单独或联合抗组胺药、磷酸二酯酶4抑制剂或皮质类固醇来治疗鼻炎
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
WO2005105765A1 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
WO2009072950A1 (en) * 2007-12-07 2009-06-11 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
WO2010091198A1 (en) 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes
EP2453894B1 (en) 2009-07-15 2015-11-04 Theravance Biopharma R&D IP, LLC Crystalline freebase form of a biphenyl compound
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2883543B1 (en) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
ES2660317T3 (es) 2013-03-15 2018-03-21 Verona Pharma Plc Combinación de fármacos
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
AU2015261239B2 (en) 2014-05-12 2020-02-27 Verona Pharma Plc New treatment
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
CA3225993A1 (en) 2018-02-08 2019-08-15 University Of Southern California The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
CA2216919C (en) 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres comprising a biocompatible polysaccharide
PT1393721E (pt) 1997-03-20 2009-02-02 Schering Corp Forma de dosagem de aglomerados de pó

Also Published As

Publication number Publication date
NO20012514D0 (no) 2001-05-22
SE9804000D0 (sv) 1998-11-23
IL143040A0 (en) 2002-04-21
IL143040A (en) 2009-09-01
NO20012514L (no) 2001-07-19
DE69930158D1 (de) 2006-04-27
CA2349633A1 (en) 2000-06-02
EE200100275A (et) 2002-10-15
PL348523A1 (en) 2002-06-03
HUP0104182A2 (hu) 2002-03-28
CN1198592C (zh) 2005-04-27
CY1105609T1 (el) 2010-07-28
US6475524B1 (en) 2002-11-05
WO2000030614A1 (en) 2000-06-02
BR9915592A (pt) 2001-08-07
ZA200103946B (en) 2002-10-30
JP4447169B2 (ja) 2010-04-07
SK7032001A3 (en) 2001-11-06
EP1133285A1 (en) 2001-09-19
ES2258865T3 (es) 2006-09-01
DE69930158T2 (de) 2006-11-16
NZ511494A (en) 2003-11-28
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
AU2010400A (en) 2000-06-13
CZ20011778A3 (cs) 2001-08-15
KR20010080534A (ko) 2001-08-22
EP1133285B1 (en) 2006-03-01
PT1133285E (pt) 2006-06-30
CA2349633C (en) 2009-06-02
DK1133285T3 (da) 2006-06-06
AU767313B2 (en) 2003-11-06
TR200101424T2 (tr) 2001-12-21
JP2002530319A (ja) 2002-09-17
KR100697780B1 (ko) 2007-03-21

Similar Documents

Publication Publication Date Title
IS5946A (is) Aðferð til að búa til agnir þar sem myndlausu og/eða hálfstöðugu svæði hefur verið umbreytt á kristallaform
SE9804001D0 (sv) New process
WO2002055017A3 (en) Method of treating autoimmune diseases
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
DE60018881D1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
UA48946C2 (uk) Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
SE9603725D0 (sv) New teatment
IL123001A0 (en) Analgesic from snake venom
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
ATE474552T1 (de) ßFESTE DOSIERUNGSFORM ZUR OKULAREN APPLIKATION EINER WIRKSUBSTANZ, LÖSLICHE, FESTE OPHTHALMISCHE EINLAGE SOWIE HERSTELLUNGSVERFAHREN DAFÜRß
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
CN1069196C (zh) 利福平在制备治疗淋病用的药物中的应用
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
HUP0300043A2 (en) Method and composition for the treatment of pain
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
WO2004033472A8 (de) Verfahren zur herstellung von monomeren uronsäuren, insbesondere d-mannuronsäure und d-guluronsäure, derivaten davon und deren verwendung als arzneimittel
RU93044740A (ru) Гетероциклические соединения, способ их получения, применение и фармацевтическая композиция
UA42478A (uk) Спосіб лікування алкоголізму